Despite the widespread use of prostate-specific antigen (PSA) as a noninvasive screening tool for PCa, the low specificity of PSA has led to an increase in either overdiagnosis or unnecessary biopsies, especially when its value is within the PSA gray zone (4–10 ng/ml) (2, 3). The gene discussed is KLK3; the disease is posterior cortical atrophy.